8-K: TG Therapeutics: Positive Subcutaneous BRIUMVI Phase 1 Data

TG Therapeutics announced positive Phase 1 data for its subcutaneous BRIUMVI formulation, supporting quarterly dosing and potentially expanding market opportunity for multiple sclerosis treatment.

Summary

• TG Therapeutics reported positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from a Phase 1 clinical trial of a subcutaneous formulation of ublituximab (BRIUMVI).
• The data supports a quarterly subcutaneous BRIUMVI dosing regimen, which is currently being evaluated in a Phase 3 trial.
• The subcutaneous formulation was well-tolerated with no new safety signals observed, and local injection-site reactions were infrequent (less than 5%).
• The trial showed mean bioavailability of subcutaneous BRIUMVI greater than 60% relative to IV administration.
• PK modeling suggests that both quarterly and every-other-month subcutaneous dosing regimens in the Phase 3 trial would achieve non-inferior total drug exposure compared to IV BRIUMVI.
• The Phase 3 trial has completed enrollment, with top-line data expected in late 2026 or early 2027.
• If approved, subcutaneous BRIUMVI could be the first self-administered, at-home, quarterly anti-CD20 therapy for multiple sclerosis, potentially doubling the addressable market.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the Phase 1 data supports the viability of a more convenient subcutaneous formulation, which could expand market reach and patient access.

Positives

• Positive PK/PD, safety, and tolerability data from the Phase 1 trial.
• Subcutaneous formulation was well-tolerated with no new safety signals.
• Mean bioavailability of subcutaneous BRIUMVI was greater than 60% relative to IV administration.
• PK modeling supports non-inferior drug exposure for both quarterly and every-other-month subcutaneous dosing regimens in Phase 3.
• Potential to offer the first self-administered, at-home, quarterly anti-CD20 therapy for MS.
• Strategic potential to nearly double the addressable market for the BRIUMVI franchise.
• Phase 3 trial enrollment is complete, with data expected soon.

Negatives

• Systemic injection-related reactions occurred in approximately 21% of patients, though they were not dose-dependent and resolved in all patients.
• The risk of serious infections (5% in MS trials) and infusion reactions (48% with premedication) remains a concern, consistent with the known profile of IV BRIUMVI.
• Potential for liver injury and HBV reactivation are listed as warnings and precautions.
• The company faces risks related to regulatory approvals, market acceptance, and competition.

Risks

• The risk that the Phase 3 subcutaneous BRIUMVI program will not meet its primary endpoint or lead to regulatory approval.
• Potential for variations in market potential due to regulatory limitations on labeling.
• Reliance on third parties for manufacturing, distribution, and supply chain.
• The possibility that individual patient experiences in the post-marketing setting may differ from clinical trials.
• Uncertainty regarding the commercial acceptance of a subcutaneous formulation.
• Potential delays in clinical trial readouts due to enrollment, data collection, or other factors.
• Competition from other anti-CD20 therapies and emerging treatments for multiple sclerosis.

Future Outlook

Top-line data from the Phase 3 trial evaluating subcutaneous BRIUMVI is expected in late 2026 or early 2027. If successful, the company anticipates advancing toward a potential approval in 2028. The company also plans to commence a device bridging study for an autoinjector device later this year.

Management Comments

• "We are very pleased to report these positive Phase 1 results demonstrating that our proprietary high-concentration, low-volume subcutaneous formulation of BRIUMVI was well tolerated and achieved sustained drug exposure."
• "Importantly, these data strengthen our confidence that the quarterly subcutaneous dosing regimen, currently being evaluated in the ongoing Phase 3 study, can achieve its primary endpoint."
• "If approved, subcutaneous BRIUMVI would be the first and only self-administered, at-home, quarterly anti-CD20 therapy for people living with multiple sclerosis, significantly reducing the total number of injections per year as compared to currently available options."
• "Strategically, given the distinct nature of the self-administered portion of the anti-CD20 market, a subcutaneous option could nearly double the addressable market opportunity for the BRIUMVI franchise."
• "We look forward to reporting Phase 3 data later this year or early next year and, if successful, advancing toward a potential approval in 2028."

Industry Context

StockSavvy.ai notes that the development of a subcutaneous formulation for BRIUMVI aligns with a broader industry trend towards patient-friendly, at-home administration of chronic disease therapies, particularly in the autoimmune and oncology spaces. This move by TG Therapeutics aims to enhance patient convenience and potentially capture a larger market share by offering a differentiated delivery method compared to existing intravenous treatments.

Stakeholder Impact

• Shareholders: Potential for increased market share and revenue if subcutaneous BRIUMVI is approved and commercially successful.
• Patients: Improved treatment convenience through self-administration at home, reducing the need for clinic visits.
• Healthcare Professionals: May offer a more convenient option for managing MS patients, potentially freeing up infusion center capacity.
• Payors: May influence coverage decisions based on comparative efficacy, safety, and cost-effectiveness of the subcutaneous versus IV formulation.

Next Steps

• Present final data through 24-weeks from the Phase 1 trial at a future medical meeting.
• Commence a device bridging study for an autoinjector device later this year.
• Report top-line Phase 3 data in late 2026 or early 2027.
• Advance toward potential approval of subcutaneous BRIUMVI in 2028 if Phase 3 is successful.

Key Dates

Recommendation

The positive Phase 1 data for subcutaneous BRIUMVI is encouraging and supports the company's strategy to expand market access. However, the ultimate success hinges on the upcoming Phase 3 data and subsequent regulatory approval and commercial adoption. Given the remaining clinical and regulatory hurdles, a 'hold' recommendation is prudent, awaiting further de-risking events.

Keywords

TG Therapeutics, BRIUMVI, ublituximab, subcutaneous, multiple sclerosis, Phase 1 trial, Phase 3 trial, pharmacokinetics